Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

Wyeth is now a wholly owned subsidiary of Pfizer480 enrolled

Overview

The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

480

Conditions

Major Depressive Disorder

Interventions

DVS-SR 50 mgDRUG

DVS-SR 100 mgDRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of major depressive disorder * Must be able to swallow tablets * Must be at least 18 years of age. Exclusion Criteria: * Clinical diagnosis of other psychiatric disorders * Significant risk of suicide * Unstable medical conditions.

Locations (25)

Unnamed facility

Beverly Hills, California, United States

Unnamed facility

Northridge, California, United States

Outcomes

Primary Outcomes

The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS SR versus subjects receiving placebo.

Secondary Outcomes

Additional objectives include testing both general and functional quality-of-life outcomes and satisfaction with therapy reported by the subject.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.